BioCentury | May 26, 2014
Clinical News

ELI-202: Pivotal trial started

...began an open-label, three-way crossover, U.S. pivotal bioequivalence trial to compare a single dose of ELI-202...
...3 treatments, but declined to disclose additional details. Elite Pharmaceuticals Inc. (OTCBB:ELTP), Northvale, N.J. Product: ELI-202...
BioCentury | May 26, 2014
Clinical News

ELI-202: Pivotal trial started

...began an open-label, two-way crossover, U.S. pivotal bioequivalence trial to compare a single dose of ELI-202...
...2 treatments, but declined to disclose additional details. Elite Pharmaceuticals Inc. (OTCBB:ELTP), Northvale, N.J. Product: ELI-202...
Items per page:
1 - 2 of 2